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ABSTRACT 
 
Type 2 diabetes mellitus in humans is associated with increased de novo lipogenesis (DNL), 
increased fatty acid (FA)-flux from peripheral tissues, decreased FA oxidation and hepatic 
steatosis. In type 2 diabetes mellitus, production of VLDL is increased and resistant to the 
suppressive effects of insulin. The relationships between FA metabolism, hepatic steatosis and 
VLDL production are incompletely understood. We investigated VLDL formation in relation 
to DNL and insulin sensitivity in female ob/ob mice, a model of type 2 diabetes with hepatic 
steatosis. Hepatic triglyceride (5-fold) and cholesteryl ester (15-fold) contents were increased 
in ob/ob mice compared to lean controls. Hepatic DNL was increased ~10-fold in ob/ob mice 
whereas hepatic cholesterol synthesis was not affected. Basal rates of hepatic VLDL-
triglyceride and -apoB100 production were also similar between the groups. 
Hyperinsulinemic clamping reduced VLDL-triglyceride and -apoB100 production rate by 
~60% and ~75%, respectively, in lean mice but only by ~20% and ~20%, respectively, in 
ob/ob mice. No difference in hepatic expression of genes encoding apolipoprotein B, 
microsomal triglyceride transfer protein and diacylglycerolacyltransferase-1 were found. 
Hepatic gene expression and protein phosphorylation of the insulin receptor and insulin 
receptor substrate-isoforms were reduced in ob/ob mice. Thus, strongly induced hepatic DNL 
is not associated with increased basal VLDL production in ob/ob mice, which might be 
related to differential hepatic zonation of apoB synthesis (periportal) and lipid accumulation 
(perivenous) and/or relatively low rates of cholesterogenesis. Insulin is unable to effectively 
suppress VLDL-triglyceride production in ob/ob mice, presumably due to impaired insulin 
signaling. 
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INTRODUCTION 
 
Type 2 diabetes mellitus (DM2) is associated with increased de novo lipogenesis (DNL), 
decreased plasma fatty acid (FA) oxidation and an increased FA-flux from peripheral tissues 
to the liver (1). These factors may all contribute to hepatic steatosis and increased hepatic 
VLDL production, two characteristic hallmarks of type 2 diabetes (2), and are probably 
related to insulin resistance. The relative contribution of the various pathways in hepatic lipid 
metabolism to the development of a fatty liver and disturbances in VLDL production is 
unknown but may, at least in part, be related to the localization of these processes within the 
liver. Fatty acid synthesis and TG accumulation occur predominantly in the perivenous areas 
(zone 3) of the liver whereas FA oxidation is more associated with the periportal areas (zone 
1) of the liver (3,4). VLDL secretion has not been restricted to a specific hepatic zone: 
zonation of apoB gene expression and/or synthesis has not been reported. 
Leptin-deficient ob/ob mice develop a fatty liver, insulin resistance and hyperlipidemia 
(5-7). The contribution of hepatic lipoprotein production to the development of 
hyperlipidemia in these mice is not clear. Hyperglycemia together with an increased 
glycolytic activity in ob/ob mice may lead to an increased availability of acetylCoA residues 
for DNL (8). The high glycolytic rate in these mice is reflected by increased expression levels 
and activities of enzymes involved in this metabolic pathway, i.e., glucokinase (9,10), 
phosphofructokinase (8) and pyruvate kinase (8,9). Furthermore, elevated plasma FFA levels 
(10) together with increased hepatic expression of fatty acid translocase (FAT or CD36) and 
plasma membrane-fatty acid binding protein (pmFABP) have been reported in this model 
(11). Increased endoplasmic reticulum (ER)-associated acetylCoA synthase (ACS) activity 
may increase the FA availability for esterification rather than for oxidation (11), which could 
contribute in increased TG and cholesteryl ester deposition and/or incorporation into VLDL. 
Hepatic insulin resistance seen in DM2 is associated with increased VLDL production 
(2). Acute hyperinsulinemia reduces VLDL production in healthy volunteers (12-14) but not 
in DM2 patients (2) and obese individuals (13). Despite the insulin resistant condition and an 
increased hepatic TG content in ob/ob mice, a decreased VLDL-TG production rate under 
basal fasted conditions has been reported in this model (15,16). However, increased VLDL-
TG secretion in ob/ob mice associated with enhanced expression and activity of the 
microsomal triglyceride transfer protein (MTP) has also been reported (17). The reason for 
these discrepant observations is unknown. The impact of insulin on VLDL production in the 
ob/ob mouse model has not been reported previously. Therefore, we quantified hepatic DNL 
and cholesterol synthesis using mass isotopomer distribution analysis (MIDA) and related the 
synthesis rates to VLDL-TG and -apoB100 production rates determined under basal 
conditions and during hyperinsulinemic clamp conditions in ob/ob mice and in lean 
littermates. Hepatic insulin signaling and expression levels of genes encoding transcription 
factors and important enzymes involved in fatty acid and cholesterol metabolism, VLDL 
formation and insulin signaling, were studied to provide a mechanistic basis for our findings. 
 
 
MATERIAL AND METHODS 
 
Animals. Female ob/ob and lean littermates were purchased from Harlan (Zeist, The 
Netherlands) and housed in a light- and temperature controlled facility. Experimental 
protocols were approved by the local Experimental Ethical Committee for Animal 
Experiments.  
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Analytical kits. Plasma and hepatic TG, cholesterol and glucose levels were determined by 
commercially available kits (Roche, Mannheim, Germany). Plasma and hepatic phospholipid 
concentrations and plasma FFA concentrations were determined with Phospholipid-kit and 
NEFA-C kit, respectively (Wako Chemical GmbH, Neuss, Germany). Plasma insulin was 
determined by a radio-immunoassay (RIA) RI-13K (Linco Research, Inc., St. Charles). 
 
Experimental procedures. Female ob/ob (n=5) and lean mice (n=5), weighing between 51-
63 gram and 24-28 gram respectively, were fed normal chow diet (RMH-B 2181, Hope Farms 
BV, Woerden, The Netherlands) enriched with 2% [1-
13
C]-acetate (Isotec, Miamisburg, OH), 
which was given ad libitum. After 11 days mice were fasted for a period of 4 hours. Mice 
were anaesthetized with halotane and the liver was excised. A portion of abdominal fat was 
also collected. Liver and fat tissue were immediately frozen in liquid nitrogen and stored at -
80ºC. Blood was isolated by heart puncture and immediately placed on ice in EDTA 
containing tubes and centrifuged 10 minutes at 5,000 rpm at 4ºC. Plasma was stored at -20ºC 
until analysis. 
 
Hyperinsulinemic clamp. To study the effects of insulin on lipoprotein metabolism a second 
groups of lean and ob/ob mice received a hyperinsulinemic clamp or a saline infusion 
(n=4/group) under anesthesia. Based on euglycemic insulin clamps performed in rats and 
mice by Hawkins and Rossetti et al. (18,19) where insulin concentrations were fixed at ~25 
ng/ml we used a single infusate containing all constituents, aimed to result in 
hyperinsulinemia and euglycemia. The procedure was tested in pilot experiments. The 
infusate contained insulin (18 mU/kg/min; Novo Nordisk, Bagsvaerd, Denmark), somatostatin 
(1.5 µg/kg/min; UCB, Breda, The Netherlands) to suppress the endogenous insulin 
production, and glucose (25 mg/kg/hr; Merck, Darmstadt, Germany) to maintain normal 
plasma glucose concentration. All components were freshly prepared in saline containing 
1.5% BSA (Sigma, St. Louis, MO). Plasma glucose concentration was determined with a 
GlucoTouch-glucose analyzer (LifeScan, Beerse, Belgium). The total infusion time was 2 
hours. After 1 hour mice received a Triton WR1339 infusion (Tyloxpol; Sigma, St. Louis, 
MO) 12% 
wt
/wt solution dissolved in saline, dose 5 ml/kg lean BW. Triton blocks the lipolysis 
of secreted lipoprotein particles, therefore, the accumulation of these lipoprotein particles in 
time allows us to calculate production rates (20). After injection blood samples were taken 
after 30 and 60 minutes. At the end of the experiment a 200 µl plasma sample was obtained 
by heart puncture to isolate VLDL particles. VLDL production rates were calculated from the 
slope of the linear-TG-accumulation-curves in time. Particles were isolated using a solution of 
15.3% NaCl and 35.4% KBr (final concentration 0.65% and 1.52%, respectively) in saline 
with a density <1.019 g/ml.  Plasma (0.2 ml) was used with 0.8 ml of the NaCl-KBr solution 
and centrifuged for 100 minutes at 120,000 rpm and 4ºC. Tubes were sliced at 1.5 cm from 
top and the top-fraction, containing the VLDL-particles, was collected and frozen at -80ºC 
until composition analysis and apoB quantification. VLDL particle size was determined in 
isolated VLDL fractions using a Submicron Particle Sizer, (Autodilute, model 370; Nicomp, 
Santa Barbara, CA, US). 
 
Liver lipid analysis. Liver lipids were extracted following a modified Bligh & Dyer method 
(21) and determined by commercially available kits. Total protein of tissue homogenates was 
determined using the method described by Lowry et al. (22). 
 
Histology. To study the localization of hepatic TG accumulation and VLDL production, liver 
morphology, neutral lipids and apolipoprotein B (apoB) mRNA were visualized as indicators 
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for TG deposition and VLDL formation, respectively. Hepatic morphology was visualized by 
standard Hematoxilin Eosin (HE)-staining and neutral lipids were visualized by "Oil-Red-O" 
(ORO) staining. ApoB in situ hybridization technique was described previously for apoE (23). 
The pGEM-3z vector in which apoB cDNA was placed was a gift form dr. H.M. Prinsen 
(TNO, Leiden). 
 
Mass isotopomer distribution analysis. The MIDA technique allows measuring the 
biosynthesis of polymers in vivo and is described in great detail elsewhere (24,25). Briefly, 
the relative abundance of different mass isotopomers during feeding of a [1-
13
C]-acetate-
enriched diet was determined. The enrichment of the pool of acetylCoA precursor units (p) 
that has entered newly synthesized cholesterol and palmitate can be calculated by comparing 
it with a theoretical table generated using binomial expansion and known isotope frequencies 
of the atomic isotopes. When the enrichment of the acetylCoA pool is known it becomes 
possible to calculate the fraction (f) of newly synthesized cholesterol and palmitate molecules 
in liver and adipose tissue homogenates. To determine the absolute amount of newly 
synthesized hepatic cholesterol and palmitate we multiplied f by the total amount of hepatic 
free cholesterol and palmitate, respectively. 
 
Gas chromatography/mass spectrometry (GC/MS) analysis. Plasma cholesterol was 
extracted and derivatized as described elsewhere (26). Palmitate from plasma and liver 
samples were trans-methylated according to Lepage et al. (27). Cholesterol and fatty acid 
derivates were analyzed on a magnetic sector mass spectrometer (70-250S; VG, Manchester, 
U.K.) using a Chrompack CP-Sil 19 column (Middelburg, the Netherlands) for assessment of 
isotopomer distribution patterns. For cholesterol samples, the oven temperature increased 
from 120 to 260ºC at a rate of 20ºC/min, from 260 to 280ºC at 2.5ºC/min and finally from 280 
to 300ºC at 20ºC/min. The ions at m/z 368 to 371 were measured under selected ion 
recording. For FA samples the oven temperature increased from 100 to 300ºC at a rate of 
12.5ºC/min. The ions of the palmitate derivative were measured at m/z 270 to 272 under 
selected ion recording. FA methyl esters were separated and quantified by gas liquid 
chromatography as earlier described (28) using heptadecanoic acid (17:0) as internal standard. 
 
ApoB quantification. ApoB100 concentrations were quantified with a reference to an IDL 
apoB100 standard isolated from healthy human subjects (29). Since human liver does not 
produce ApoB48 containing lipoprotein particles we were not able to quantify apoB48 levels. 
Isolated VLDL samples (10 µl) were delipidated with methanol and diethylether and dried 
under nitrogen. Delipidated lipoproteins were reduced in SDS sample buffer (8 M urea, 10 
mM Tris base, 2% SDS, 10% glycerol, 5% β-mercaptoethanol) and separated by SDS-PAGE 
using 4-15% gradient gels (Ready gels, Biorad, Hercules, CA) at 100 V for 30 minutes 
followed by 120 V for 120 minutes. Gels were either stained with a silver-staining procedure 
(29) or were prepared for Western blot analysis. Proteins were transferred on nitrocellulose 
membranes (Hybond ECL, Amersham Pharmacia Biotech, Buckinghamshire, UK) by 
Western blotting for 120 minutes at 250 mA. Blots were put on skimmed milk over night and 
stained with the primary polyclonal antibody against human apolipoprotein B, raised in sheep 
(dilution 1:100,000; Roche, Mannheim, Germany) and secondary IgG, anti-sheep antibody 
conjugated with horseradish-peroxidase activity (dilution 1:10,000; Calbiochem, San Diego, 
CA). ECL activation of the peroxidase was detected on film. ApoB100 levels were quantified 
with a reference to an IDL apoB100 standard isolated from healthy human subjects. 
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Hepatic gene expression. Hepatic gene expression levels were quantified by real time 
polymerase chain reaction (PCR) analysis during basal conditions and hyperinsulinemia. 
Total RNA was isolated from approximately 30 mg of liver tissue using Trizol-method 
(GIBCO, Paisley, UK) followed by the SV Total RNA Isolation System (Promega, Madison, 
WI) according to the protocols provided by the manufacturer. Isolated total RNA was 
converted to single stranded cDNA by a reverse transcription procedure with M-Mulv-RT 
(Boehringer Mannheim, Mannheim, Germany) according to manufacture’s protocol. cDNA 
levels were measured by real-time PCR using the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). For the PCR amplification studies, an amount 
of cDNA corresponding to 10 ng of total RNA was amplified using the qPCR core kit 
(Eurogentec, Seraing, Belgium). Procedures were essentially according to manufacturer’s 
protocol and optimised for amplification of the particular gene using the appropriate forward 
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and reverse primers (GIBCO, Paisley, UK) and a template specific 3'-TAMRA, 5'-6-FAM 
labeled Double Dye Oligonucleotide probe (Eurogentec, Seraing, Belgium). In the same 
experiments, calibration curves were run on serial dilutions of a 8x concentrated cDNA 
solution as used in the assay, resulting in a series containing 8x, 4x, 2x, 1x, 0.5x, 0.125x, 
0.062x, and 0.031x of the cDNA present in the assay incubation. Both assay and calibration 
incubations were done simultaneously. During the amplification, the breakdown of the probe 
releases the fluorescent 6-FAM-dye, resulting in an increase in fluorescence. The fluorescence 
data obtained were processed using the software program ABI Sequence Detector v1.6.3 
(System Applied Biosystems, Foster City, CA). All quantified expression levels were within 
the linear part of the calibration curves and calculated using these curves. The primers and 
probe sets used are listed in Table 1. The relative intensity of the product bands was 
determined by a CCD video camera of the ImageMaster VDS system (Pharmacia, Upsalla, 
Sweden) and quantified by Image software. 
 
Hepatic insulin signaling. For analysis of IRβ and IRS-1,2,3 phosphorylation, liver parts 
were homogenized in RIPA-buffer (30 mM Tris, pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.5% 
Triton X-100, 0.5% deoxycholate, 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 
protease inhibitors (Complete: Boehringer Mannheim)) using a Ultraturrax mixer. Lysates 
were cleared by centrifugation (14 krpm; 15 min; 4ºC). Protein content of supernatant were 
determined using BCA-kit (Pierce, Rockford, IL). A total of 25 µg of protein was analysed by 
immunoblotting for expression of IRβ subunit (Transduction Laboratories), IRS-1 (30), IRS-2 
(31) and IRS-3. Anti- IRS3 antibody was obtained by immunized rabbits with a recombinant 
His-tagged IRS3 fusion protein produced from pET16B-IRS3 (aa198-494 of rat IRS3) as 
decribed by Ouwens et al. 1994 (30).  
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RESULTS 
 
Animal characteristics. Mean body weight was 26±1 vs. 58±5 gr in the lean and ob/ob mice, 
respectively (p<0.05). Fasting plasma glucose, insulin, TG, cholesterol, and FFA 
concentrations were elevated in ob/ob mice (Table 2). Excess TG and cholesterol in ob/ob 
plasma was predominantly found in VLDL-sized fractions upon FPLC separation (data not 
shown). Liver weight (2-fold), hepatic TG (5-fold), total cholesterol (~2.6-fold), free 
cholesterol (~1.6-fold), cholesteryl ester (~15-fold) and glycogen levels (~1.8-fold) were all 
increased in ob/ob mice. No differences in hepatic phospholipid and glucose-6-phosphate 
(G6P) levels were detected between lean and ob/ob mice (Table 2). 
 Neutral fat deposition (not shown in figure) in ob/ob mice was clearly associated with 
the perivenous (zone 3) area of liver lobules resulting in enlarged hepatocytes in these parts of 
the liver (Figure 1, A vs. B). To check whether localization of fat in ob/ob liver was 
compatible with that of apolipoprotein B gene expression, Apob mRNA was visualized by in 
situ hybridization in lean and ob/ob mouse liver (Figure 1, C and D, respectively). Apob 
mRNA was present in the entire liver lobe but a stronger signal was observed in the periportal 
zone of the liver both in lean and ob/ob mice, suggesting zonal differentiation between VLDL 
formation and TG deposition in ob/ob mouse liver. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 1. Hematoxilin Eosin (HE) staining (A,B) and apoB in situ hybridization 
  (C-F) in liver slides from lean and ob/ob mice, respectively, p=portal area (zone 1), 
  c=central area (zone 3). 
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De novo lipogenesis and cholesterol synthesis. Palmitate and cholesterol synthesis rates in 
lean and ob/ob mice fed a [1-
13
C]-acetate-enriched diet are summarized in Table 3. The 
enrichment of acetylCoA pool and fractional synthesis rate values could not be calculated in 
adipose tissue of ob/ob mice due to low isotopic enrichments. Enrichments of the hepatic 
actylCoA pools for DNL and cholesterogenesis were similar and not different between lean 
and ob/ob mice. Hepatic fractional de novo lipogenesis (DNL) was increased 1.7-fold in ob/ob 
mice in comparison with lean controls. The absolute amount of newly synthesized hepatic 
palmitate was 10-fold higher in livers of ob/ob mice than in those from controls. DNL could 
not be quantified in adipose tissue from ob/ob mice: values in lean controls indicate that 
adipocytes may significantly contribute to total DNL. 
The fractional hepatic cholesterol synthesis was decreased ~1.4 fold in ob/ob mice 
compared to lean mice. Values for hepatic free cholesterol contents from Table 2 were used to 
calculate the total amount of newly synthesized cholesterol present in the liver, which was 
similar in lean and ob/ob mice (Table 3). 
To understand the molecular basis of the differences in hepatic lipid synthesis and 
contents between lean and ob/ob mice, expression levels of relevant genes were determined. 
Expression levels of key genes involved in FA synthesis, i.e. fatty acid synthase (Fas), and 
acylCoA carboxylase (Acc) were clearly increased in livers of ob/ob mice. The mRNA levels 
for the transcription factor sterol regulatory element binding protein-1c (Srebp-1c) was also 
increased, but gene expression of liver X receptor (Lxr) and carbohydrate responsive element-
binding protein (Chrebp), also implicated in control of Fas expression, were significantly 
decreased. Expression level of the sterol regulatory binding element protein-2 (Srebp-2), the 
transcription factor mainly involved in control of cholesterol synthesis, was decreased in 
ob/ob mice liver but this did not result in reduced expression of its target gene HMGCoA 
reductase (Hmgr). Hepatic expression levels of the transcription factor peroxisomal 
proliferator activated receptor-α (Ppar-α) was decreased but the expression level of Ppar-γ 
was increased in ob/ob mouse liver. Genes involved in β-oxidation, that are controlled by 
PPARα, i.e., mitochondrial HMGCoA-synthase (Hmgs), carnitine palmitoyl transferase-1a 
(Cpt1a) and medium chain acyl dehydrogenase (Mcad), tended to decrease in ob/ob mice, 
suggesting a decreased β-oxidation in ob/ob mouse liver (Figure 2B). 
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Hepatic VLDL production under basal conditions and hyperinsulinemic clamp. VLDL-
TG and apoB100 production was measured in anesthetized lean and ob/ob mice during saline 
infusion (control) and during a hyperinsulinemic clamp. During the hyperinsulinemic clamp, 
plasma glucose levels were clamped at basal, fasting (9 hr) plasma concentrations and were 
reached within 60 minutes. Average plasma glucose levels were 7±1 mM and 15±1 mM for 
lean and ob/ob mice, respectively (Figure 3A). Plasma insulin increased to stable levels of 
34±3 ng/ml and 34±2 ng/ml in lean and ob/ob mice, respectively (Figure 3B). Saline infused 
mice maintained their fasting insulin level during the clamp (0.7±0.4 ng/ml and 5±2 ng/ml in 
lean and ob/ob mice, respectively). Plasma FFA levels decreased in the insulin-infused mice 
only (Figure 3C). Although ob/ob mice have higher basal plasma FFA concentrations, insulin 
reduced plasma FFA levels to the same concentration within 60 minutes as in lean mice. 
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After 60 minutes of saline infusion or hyperinsulinemia, Triton WR1339 was injected to 
determine VLDL-TG and apoB100 production rates. Basal VLDL-TG production rates were 
similar in lean and ob/ob mice (64±14 and 52±7 µmol/kg/hr, respectively, Figure 4A). Acute 
hyperinsulinemia reduced VLDL-TG production rate to 27±1 µmol/kg/hr (-58%) in lean mice 
but only to 41±1 µmol/kg/hr (-21%) in ob/ob mice (Figure 4A). ApoB100 production 
determined by Western blotting procedure showed a similar pattern as VLDL-TG production 
rates during the insulin clamp. Insulin suppressed apoB100 production much more 
pronounced in lean mice than in ob/ob mice (Figure 4B). The apoB100/B48 ratio in nascent 
VLDL particles, as determined by intensity scanning of Western blots, was much higher in 
ob/ob mice than in lean controls: this ratio was decreased by insulin infusion. 
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Expression of genes encoding structural proteins of VLDL particles, i.e., apoB and apoE, was 
similar in liver of lean and ob/ob mice. In spite of the increased apoB100/B48 ratio in ob/ob 
VLDL, expression of apobec-1, encoding the Apob mRNA-editing protein, was not different 
between both groups indicating a posttranscriptional upregulation of editing activity in ob/ob 
mice. Expression of the genes encoding MTP and DGAT, enzymes essential for VLDL 
lipidation, did not differ between lean and ob/ob mice (Figure 2C). 
 
Insulin signaling. Hepatic gene expression levels of the insulin receptor (Ir) and insulin 
receptor substrate isoforms (Irs1 and Irs2) were decreased in ob/ob mice (Figure 5A). Also, 
phosphorylation of IRβ, IRS-1 and IRS-2 proteins was reduced in ob/ob mice liver (Figure 
5B), indicating decreased hepatic insulin signaling. IRS-3 phosphorylation was slightly 
increased in ob/ob mice liver (Figure 5B). 
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DISCUSSION 
 
The primary defect in the ob/ob mouse model is the absence of leptin, resulting in an obese 
and diabetic phenotype (5). Ob/ob mice have increased plasma FFA levels, a 10-fold increase 
in hepatic de novo lipogenesis (DNL) and a severe, perivenous localized, hepatic steatosis. 
Despite these diabetic characteristics, hepatic VLDL production was not increased, as is the 
case in humans with insulin resistance. We propose that absence of a simultaneous 
appropriate upregulation of hepatic cholesterol synthesis, recognized as a crucial factor in 
control of VLDL production rates (32-35) contributes to this discordant phenotype. We 
further demonstrated that the VLDL production process in ob/ob mice was insensitive to the 
suppressive effects of insulin, as previously reported in human (2,13) and rodent (36) insulin 
resistant conditions. This is likely the result of a decrease in the transduction pathway of 
insulin: in livers of ob/ob mice IRβ, IRS-1 and IRS-2 gene expression levels and protein 
phosphorylation were clearly decreased. Similar decreases of hepatic and muscle IRS 
phosphorylation after insulin stimulation in vivo were observed in other studies (37-40). 
We found DNL, suggested to be a regulator of VLDL production, to be 10-fold 
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increased in ob/ob liver using MIDA approach. The increase in DNL is probably related to 
dysregulation of transcriptional control of this pathway due to leptin-deficiency. Expression 
of enzymes involved in the lipogenesis is under control of at least three transcription factors, 
i.e., SREBP-1c, LXR and CHREBP (41-43). Interestingly, hepatic SREBP-1c expression 
levels were increased in ob/ob mice, whereas LXR and CHREBP expression levels were 
decreased, indicating that SREBP-1c is independently able to strongly induce DNL. SREBP-
1c expression is influenced by insulin (44,45). Insulin levels are elevated in ob/ob mouse and 
may continuously induce expression of SREBP-1c and, thereby, of its target genes (41). Thus, 
insulin resistance may not involve all branches of insulin signaling. Alternatively, leptin has 
been shown to be able to downregulate SREBP-1c expression and protein levels and 
expression of its target gene (Fas) in ob/ob adipocytes (46) and in wildtype mouse liver (47). 
IRS2
-/-
 mice, like ob/ob mice, have increased hepatic SREBP-1c levels, which normalize upon 
leptin treatment (48). Irrespective of the underlying mechanism, however, our results indicate 
that upregulated DNL per se is not a regulator of hepatic VLDL production by mouse liver. 
Theoretically, it may be that TG and apoB, required for VLDL assembly, are 
functionally separated in the ob/ob liver. Using in situ hybridization, we found that Apob 
mRNA is present in all cells in the liver lobule, but with highest intensity in periportal 
hepatocytes of control mice. Funahashi et al. (49) reported a uniform distribution of Apob 
mRNA in rat liver, suggesting the existence of species-differences in this respect. In any case, 
our results suggest that perivenously localized TG may be less available for VLDL 
production.  
VLDL production in ob/ob mice has been reported to be decreased (15,16) and 
increased (17) in comparison of that in lean controls. In this study, we found a moderate, not 
statistically significant decrease in VLDL-TG production in female ob/ob mice under basal 
conditions (Figure 4A). Although basal production rates for VLDL-TG and -apoB100 were 
similar in ob/ob and lean mice, acute hyperinsulinemia did not decrease these production rates 
to the same extent in both genotypes. The insulin-insensitivity in ob/ob mice may lead to a 
relative overproduction of VLDL particles in postprandial conditions and hence contribute to 
the hypertriglyceridemia seen in these mice. 
In our clamp experiments plasma insulin levels were similar between both groups. 
However, both groups were clamped at their basal glucose levels resulting in higher glucose 
levels in ob/ob mice. The question arises to which extent this may have influenced our results 
with respect to insulin sensitivity of VLDL-TG production. For instance, it may be argued 
that hyperglycemia in the presence of hyperinsulinemia may stimulate DNL further. This 
effect might counteract the inhibitory effects of insulin on VLDL-TG secretion. However, in 
the basal state VLDL production was not increased despite hyperglycemia and a manyfold 
increase in DNL in ob/ob mice, indicating that this was not a driving force for VLDL 
secretion. Therefore, it is rather unlikely that hyperglycemia per se the profound insulin 
resistance with respect to the suppressive effects on VLDL production. 
Substrate availability has been proposed to regulate hepatic VLDL output (32,35). 
Since the availability of plasma FFA, de novo synthesized FA and hepatic TG were all 
increased in ob/ob mice, it is unlikely that the supply of TG is rate-controlling in this respect. 
In addition, the availability of newly synthesized cholesterol may influence VLDL formation, 
as has been shown in rats (32), pigs (33), rabbits (34) and in humans treated with cholesterol 
synthesis inhibitors (35). Total hepatic cholesterol content in ob/ob mouse liver was increased 
but the absolute cholesterol synthesis rate, as determined by MIDA, was not different 
compared to lean mice. The transcription factor that is in control of cholesterol synthesis is 
the sterol regulatory element binding protein-2 (SREBP-2). Sterol regulation is the primary 
mechanism that dominates cleavage of intracellular, membrane-bound SREBP-2, allowing 
entry of the active transcription factor into the nucleus to induce expression levels of genes 
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involved in cholesterol synthesis and uptake. Increased hepatic cholesterol levels were 
associated with a decreased expression level of SREBP-2 in ob/ob mice, however, this 
decrease in SREBP-2 expression did not decrease the expression levels of its target gene 
HMGCoA reductase (Figure 2) nor the absolute cholesterol synthesis rate (Table 3). We 
hypothesize that limited availability of newly synthesized cholesterol reduces the ability of 
the liver to remove excess TG as VLDL. 
In conclusion, hepatic cholesterol synthesis is not affected but DNL is clearly 
increased in ob/ob mice, probably related to increased SREBP-1c expression levels and 
despite downregulation of LXR and CHREBP expression. Insufficient supply of newly 
synthesized cholesterol may become rate-controlling for VLDL production in ob/ob mice in a 
situation in which the supply of FA from plasma and DNL is excessive. Metabolic zonation of 
TG accumulation and apoB production may contribute in this respect. The inability to induce 
VLDL-production under these conditions, in combination with impaired hepatic β-oxidation, 
contributes to development of hepatic steatosis, which in itself may contribute to development 
of hepatic insulin resistance. Hepatic insulin signaling is clearly impaired in ob/ob mice 
resulting in a decreased ability of insulin to suppress VLDL production. 
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